|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
NMDA receptor antagonist
|
|
gptkbp:administeredBy
|
nasal spray
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AX27
|
|
gptkbp:bioavailability
|
48%
|
|
gptkbp:brand
|
gptkb:Spravato
|
|
gptkbp:CASNumber
|
gptkb:33643-46-8
|
|
gptkbp:category
|
analgesic
dissociative
antidepressant
|
|
gptkbp:chemicalFormula
|
C13H16ClNO
|
|
gptkbp:chirality
|
S-enantiomer of ketamine
|
|
gptkbp:contraindication
|
intracerebral hemorrhage
aneurysmal vascular disease
hypersensitivity to esketamine
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:discoveredBy
|
gptkb:Calvin_Stevens
|
|
gptkbp:eliminationHalfLife
|
7-12 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1962
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Esketamine
|
|
gptkbp:IUPACName
|
(S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonist
|
|
gptkbp:meltingPoint
|
237–239 °C
|
|
gptkbp:metabolism
|
gptkb:ketamine
liver
|
|
gptkbp:molecularWeight
|
237.73 g/mol
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:proteinBinding
|
43-45%
|
|
gptkbp:PubChem_CID
|
123590
|
|
gptkbp:relatedTo
|
gptkb:ketamine
|
|
gptkbp:riskFactor
|
abuse
dependence
|
|
gptkbp:routeOfAdministration
|
intravenous
intranasal
|
|
gptkbp:sideEffect
|
nausea
dizziness
dissociation
sedation
increased blood pressure
|
|
gptkbp:smiles
|
CN[C@@H](C1CCCCC1=O)C2=CC=CC=C2Cl
|
|
gptkbp:synonym
|
gptkb:(S)-ketamine
gptkb:S-ketamine
|
|
gptkbp:UNII
|
U3G4F82R0M
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
treatment-resistant depression
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|